{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:27:20Z","timestamp":1794360440745,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41434-025-00554-5","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T12:34:25Z","timestamp":1754138065000},"page":"573-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dystrophin\/mini-dystrophin expression analysis by immunoaffinity liquid chromatography\u2013tandem mass spectrometry after gene therapy for DMD"],"prefix":"10.1038","volume":"32","author":[{"given":"Jason","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Palandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Duriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Beidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Binks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8476-5427","authenticated-orcid":false,"given":"Hendrik","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"554_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919\u201328. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4.","journal-title":"Cell"},{"key":"554_CR2","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","volume":"394","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, Bonnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394:2025\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)32910-1.","journal-title":"Lancet"},{"key":"554_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Prim. 2021;7:13 https:\/\/doi.org\/10.1038\/s41572-021-00248-3.","journal-title":"Nat Rev Dis Prim"},{"key":"554_CR4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","volume":"24","author":"JK Mah","year":"2014","unstructured":"Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24:482\u201391. https:\/\/doi.org\/10.1016\/j.nmd.2014.03.008.","journal-title":"Neuromuscul Disord"},{"key":"554_CR5","unstructured":"Parent Project Muscular Dystrophy (PPMD). What is Duchenne? Duchenne 101. 2024 https:\/\/www.parentprojectmd.org\/about-duchenne\/what-is-duchenne\/about-duchenne-and-becker\/ (accessed 05 March 2024)."},{"key":"554_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/archdischild-2014-306366","volume":"99","author":"HJA van Ruiten","year":"2014","unstructured":"van Ruiten HJA, Straub V, Bushny K, Guglieri M. Improving recognition of Duchenne muscular dystrophy: a retrospective case note review. Arch Dis Child. 2014;99:1074\u20137. https:\/\/doi.org\/10.1136\/archdischild-2014-306366.","journal-title":"Arch Dis Child"},{"key":"554_CR7","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/ejhg.2014.301","volume":"23","author":"SH Wong","year":"2015","unstructured":"Wong SH, McClaren BJ, Archibald AD, Weeks A, Langmaid T, Ryan MM, et al. A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy. Eur J Hum Genet. 2015;23:1294\u2013300. https:\/\/doi.org\/10.1038\/ejhg.2014.301.","journal-title":"Eur J Hum Genet"},{"key":"554_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmuller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35:643\u201353. https:\/\/doi.org\/10.1007\/s10654-020-00613-8.","journal-title":"Eur J Epidemiol"},{"key":"554_CR9","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology. 2021;97:e2304\u2013e2314. https:\/\/doi.org\/10.1212\/WNL.0000000000012910.","journal-title":"Neurology"},{"key":"554_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3.","journal-title":"Lancet Neurol"},{"key":"554_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391:451\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(17)32160-8.","journal-title":"Lancet"},{"key":"554_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","volume":"21","author":"T Markati","year":"2022","unstructured":"Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 2022;21:814\u201329. https:\/\/doi.org\/10.1016\/S1474-4422(22)00125-9.","journal-title":"Lancet Neurol"},{"key":"554_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859930","volume":"9","author":"C Happi Mbakam","year":"2022","unstructured":"Happi Mbakam C, Lamothe G, Tremblay JP. Therapeutic strategies for dystrophin replacement in Duchenne muscular dystrophy. Front Med (Lausanne). 2022;9:859930. https:\/\/doi.org\/10.3389\/fmed.2022.859930.","journal-title":"Front Med (Lausanne)"},{"key":"554_CR14","doi-asserted-by":"publisher","unstructured":"Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov 2023;22:917\u201334. https:\/\/doi.org\/10.1038\/s41573-023-00775-6.","DOI":"10.1038\/s41573-023-00775-6"},{"key":"554_CR15","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Compr Physiol. 2015;5:1223\u201339. https:\/\/doi.org\/10.1002\/cphy.c140048.","journal-title":"Compr Physiol"},{"key":"554_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175675","volume":"947","author":"G Patterson","year":"2023","unstructured":"Patterson G, Conner H, Groneman M, Blavo C, Parmar MS. Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach. Eur J Pharmacol. 2023;947:175675. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175675.","journal-title":"Eur J Pharmacol"},{"key":"554_CR17","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan N, Dickson G. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:S303\u2013S316. https:\/\/doi.org\/10.3233\/JND-210678.","journal-title":"J Neuromuscul Dis"},{"key":"554_CR18","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene moxeparvovec: first approval. Drugs. 2023;83:1323\u20139. https:\/\/doi.org\/10.1007\/s40265-023-01929-x.","journal-title":"Drugs"},{"key":"554_CR19","unstructured":"Sarepta Therapeutics Inc. Elevidys (delandistrogene moxeparvovec-rokl) prescribing information. 2023 https:\/\/www.elevidys.com\/PI (accessed 05 March 2024)."},{"key":"554_CR20","unstructured":"US Food & Drug Administration. FDA Approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy [media release]. 2023 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy (accessed 05 March 2024)."},{"key":"554_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.nmd.2022.12.007","volume":"33","author":"JF Boehler","year":"2023","unstructured":"Boehler JF, Brown KJ, Beatka M, Gonzalez JP, Donisa Dreghici R, Soustek-Kramer M, et al. Clinical potential of microdystrophin as a surrogate endpoint. Neuromuscul Disord. 2023;33:40\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2022.12.007.","journal-title":"Neuromuscul Disord"},{"key":"554_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1089\/hum.2022.190","volume":"34","author":"JS Chamberlain","year":"2023","unstructured":"Chamberlain JS, Robb M, Braun S, Brown KJ, Danos O, Ganot A, et al. Microdystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials. Hum Gene Ther. 2023;34:404\u201315. https:\/\/doi.org\/10.1089\/hum.2022.190.","journal-title":"Hum Gene Ther"},{"key":"554_CR23","unstructured":"Butterfield R, Shieh P, Yong F, Binks M, McDonnell TG, Ryan KA, et al. One year data from ambulatory boys in a phase 1b, open-label study of fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD). Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, Orlando, FL, March 3-6, 2024."},{"key":"554_CR24","doi-asserted-by":"publisher","unstructured":"Butterfield R, Shieh PB, Li H, Binks M, McDonnell TG, Ryan KA, et al. One-year data from ambulatory participants in a Phase 1b study of the gene therapy fordadistrogene movaparvovec for Duchenne muscular dystrophy. Nat Med. 2025; https:\/\/doi.org\/10.1038\/s41591-025-03750-3.","DOI":"10.1038\/s41591-025-03750-3"},{"key":"554_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41434-021-00300-7","volume":"29","author":"V Farrokhi","year":"2022","unstructured":"Farrokhi V, Walsh J, Palandra J, Brodfuehrer J, Caiazzo T, Owens J, et al. Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy. Gene Ther. 2022;29:608\u201315. https:\/\/doi.org\/10.1038\/s41434-021-00300-7.","journal-title":"Gene Ther"},{"key":"554_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.omtm.2023.05.017","volume":"30","author":"C Le Guiner","year":"2023","unstructured":"Le Guiner C, Xiao X, Larcher T, Lafoux A, Huchet C, Toumaniantz G, et al. Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy. Mol Ther Methods Clin Dev. 2023;30:30\u201347.\u00a0https:\/\/doi.org\/10.1016\/j.omtm.2023.05.017.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"554_CR27","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation [media release]. 2019 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation (accessed 05 March 2024)."},{"key":"554_CR28","unstructured":"US Food & Drug Administration. FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation [media release]. 2020 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation (accessed 05 March 2024)."},{"key":"554_CR29","unstructured":"US Food & Drug Administration. FDA approves targted treatment for rare Duchenne muscular dystrophy mutation [media release]. 2021 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0 (accessed 05 March 2024)."},{"key":"554_CR30","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94:e2270\u2013e2282. https:\/\/doi.org\/10.1212\/WNL.0000000000009233.","journal-title":"Neurology"},{"key":"554_CR31","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to Exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77:982\u201391. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264.","journal-title":"JAMA Neurol"},{"key":"554_CR32","doi-asserted-by":"crossref","unstructured":"Iannaccone S, Phan H, Straub V, Muntoni F, Malhotra J, Chu R, et al. Casimersen in patients with Duchenne muscular dystrophy: interim safety and muscle biopsy results from the phase 3 ESSENCE trial. Muscular Dystrophy Association (MA) Clinical and Scientific Congress, Dallas, TX, March 19-22, 2023.","DOI":"10.1016\/j.nmd.2022.07.248"},{"key":"554_CR33","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne Muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77:1122\u201331. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484.","journal-title":"JAMA Neurol"},{"key":"554_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"JR Mendell","year":"2023","unstructured":"Mendell JR, Shieh PB, McDonald CM, Sahenk Z, Lehman KJ, Lowes LP, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. 2023;11:1167762. https:\/\/doi.org\/10.3389\/fcell.2023.1167762.","journal-title":"Front Cell Dev Biol"},{"key":"554_CR35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman CM, Proud CM, McDonald CM, Lehman KJ, Goedeker NL, Mason S, et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from Study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023;94:955\u201368. https:\/\/doi.org\/10.1002\/ana.26755.","journal-title":"Ann Neurol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00554-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00554-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00554-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:38:44Z","timestamp":1766047124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00554-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00554-5","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JW, ND, AM, and HN are employees of Pfizer and have stock or stock options in Pfizer. JP, DB, and MB were employees of Pfizer at the time the study was conducted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. The protocol was approved by the relevant institutional review board or independent ethics committee at each participating study site. All participants or their parent or legal guardian provided written informed consent prior to entry into the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}